Moderna (MRNA) Melanoma Vaccine Cuts Recurrence Risk by 42% in Phase 3 Trial with Merck

Key Highlights

Table of Contents

Shares of Moderna dropped over 17% to $202.63 following unexpected early disclosure of melanoma vaccine trial data.
The combination therapy with Merck achieved a 42% reduction in melanoma recurrence or death risk and 38% reduction in distant metastasis or death risk.
Recurrence-free survival at two years reached 82.2% for patients receiving the combined regimen versus 70% for those on Keytruda monotherapy.
Both companies plan to share comprehensive findings at a medical conference on October 24 while advancing regulatory conversations.

Shares of Moderna (MRNA) tumbled more than 17% to $202.63 on Thursday following the unexpected publication of comprehensive data from its melanoma vaccine trial. The drop occurred even as the Phase 3 study achieved its primary endpoints when combined with Merck’s Keytruda therapy.

Moderna, Inc., MRNA

Unexpected Data Publication Triggers Market Response

The clinical data momentarily surfaced on a medical oncology platform ahead of the planned weekend disclosure. Following this premature appearance, Moderna and Merck chose to release the complete findings on Thursday. Trading activity saw Moderna shares plunge as much as 25% during the session, wiping out roughly $24 billion in market capitalization temporarily.

The stock clawed back a portion of those losses before the closing bell but continued sliding in Friday’s early trading. Merck experienced share price weakness following the melanoma data release. Prior to Thursday’s decline, Moderna had soared approximately 587% year-to-date.

Clinical Trial Demonstrates Significant Efficacy Benefits

The INTerpath-001 study included 1,137 participants diagnosed with high-risk stage IIB-IV melanoma following surgical resection. Study subjects were randomized to receive either the customized vaccine, intismeran autogene, paired with Keytruda or a control regimen of placebo plus Keytruda. Each vaccine dose was tailored based on specific genetic mutations identified within individual patient tumors.

At a median follow-up duration of 24.6 months, the investigational combination demonstrated a 42% risk reduction for recurrence or mortality. Recurrence-free survival at the two-year mark stood at 82.2% compared with 70% among those receiving Keytruda as monotherapy. The dual-agent approach also lowered the risk of distant metastatic spread or death by 38%.

Safety Profile and Expert Commentary

Grade 3 or higher treatment-emergent adverse events occurred in 14.2% of combination therapy recipients versus 13.4% in the comparator arm. Both pharmaceutical companies confirmed that no novel safety signals emerged during the trial. In other oncology developments, Roche shares advanced following FDA clearance of a colorectal cancer therapy earlier this week.

UBS analyst Michael Yee characterized the recurrence data as robust on balance but suggested the sell-off reflected profit-taking after substantial share appreciation. William Blair’s Myles Minter raised questions about whether comparable efficacy would translate to additional tumor types. Some analysts observed that the distant metastasis reduction fell short of projections based on preliminary research, though they acknowledged methodological differences between studies.

Tokenized Securities Movement and Next Steps

Meanwhile, Moderna Tokenized bStocks (MRNAB) was trading at $191.91, reflecting a 20.67% decline over the preceding 24-hour period. This instrument operates independently from traditional Nasdaq-listed shares. In broader digital asset markets, BNB Chain processed $25.6 billion in tokenized equity transactions throughout the third quarter.

Moderna and Merck have scheduled a detailed presentation of the trial outcomes for Saturday, October 24, during a medical conference in Madrid. Regulatory dialogue concerning the findings continues. Because overall survival data remains immature at this analysis point, the study has yet to establish a definitive mortality benefit.